The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines
Open accessAbstract
Components of the SWI/SNF chromatin-remodeling complex, such as INI1, are inactivated in human cancer and, thus, act as tumor suppressors. Here we screened for mutations the entire coding sequence of BRG1 (SMARCA4), which encodes the ATPase of the complex, in 59 lung cancer cell lines of the most common histopathological types. Mutations were detected in 24% of the cancer cell lines, many of them in cells commonly used for lung cancer research. All mutations were homozygous and most predicted truncated proteins. The alterations were significantly more frequent in the non-small-cell lung cancer (NSCLC) type (13/37, 35%) as compared to the small-cell lung cancer (SCLC) type (1/19, 5%) (P<0.05; Fisher's Exact test) and BRG1 was the fourth most frequently altered gene in NSCLC cell lines. BRG1 mutations coexisted with mutations/deletions at KRAS, LKB1, NRAS, P16, and P53. However, alterations at BRG1 always occurred in the absence of MYC amplification, suggesting a common role in lung cancer development. In conclusion, our data strongly support that BRG1 is a bona fide tumor suppressor and a major factor in lung tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, B. E., & Jaenisch, R. (2007) · Nature · doi:10.1038/nature05944 · Cited by 2,676
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
Versteege, I., Sévenet, N., Lange, J., Rousseau-Merck, M.-F., Ambros, P., Handgretinger, R., Aurias, A., & Delattre, O. (1998) · Nature · doi:10.1038/28212 · Cited by 1,556
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
A Brg1 Null Mutation in the Mouse Reveals Functional Differences among Mammalian SWI/SNF Complexes
Bultman, S., Gebuhr, T., Yee, D., La Mantia, C., Nicholson, J., Gilliam, A., Randazzo, F., Metzger, D., Chambon, P., Crabtree, G., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00127-1 · Cited by 823
The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest
Dunaief, J. L., Strober, B. E., Guha, S., Khavari, P. A., Ålin, K., Luban, J., Begemann, M., Crabtree, G. R., & Goff, S. P. (1994) · Cell · doi:10.1016/0092-8674(94)90405-7 · Cited by 624
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sánchez‐Céspedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J. M., Westra, W. H., Herman, J. G., & Sidransky, D. (2002) · PubMed · Cited by 612
BRCA1 Is Associated with a Human SWI/SNF-Related Complex
Bochar, D. A., Wang, L., Beniya, H., Kinev, A., Xue, Y., Lane, W. S., Wang, W., Kashanchi, F., & Shiekhattar, R. (2000) · Cell · doi:10.1016/s0092-8674(00)00030-1 · Cited by 546
c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function
Cheng, S.-W. G., Davies, K. P., Yung, E., Beltran, R. J., Yu, J., & Kalpana, G. V. (1999) · Nature Genetics · doi:10.1038/8811 · Cited by 396
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.
Wong, A. K., Shanahan, F., Chen, Y., Lian, L., Ha, P. C., Hendricks, K., Ghaffari, S. R., Iliev, D., Penn, B., Woodland, A.-M., et al. (2000) · PubMed · Cited by 364
Sudarsanam, P., & Winston, F. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02060-6 · Cited by 347
Cited by
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
SWI/SNF nucleosome remodellers and cancer
Wilson, B. G., & Roberts, C. W. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3068 · Cited by 1,282
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Dulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 735
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y.-J., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.006 · Cited by 654
M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer
Lan, J., Sun, L., Xu, F., Liu, L., Hu, F., Song, D., Hou, Z., Wu, W., Luo, X., Wang, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0014 · Cited by 643
The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
Shain, A. H., & Pollack, J. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055119 · Cited by 576
The SWI/SNF complex and cancer
Reisman, D., Glaros, S., & Thompson, E. A. (2009) · Oncogene · doi:10.1038/onc.2009.4 · Cited by 568
Guan, B., Wang, T.-L., & Shih, I.-M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1562 · Cited by 442
Hoffman, G. R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316793111 · Cited by 421
The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
Hodges, C., Kirkland, J. G., & Crabtree, G. R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026930 · Cited by 414
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kim, K. H., Kim, W., Howard, T. P., Vazquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 406
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Morera, L., Lübbert, M., & Jung, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0223-4 · Cited by 395
Schneppenheim, R., Frühwald, M. C., Gesk, S., Hasselblatt, M., Jeibmann, A., Kordes, U., Kreuz, M., Leuschner, I., Subero, J. I. M., Obser, T., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.01.013 · Cited by 348
Regulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to Cancer
Li, J., Poi, M. J., & Tsai, M.-D. (2011) · Biochemistry · doi:10.1021/bi200642e · Cited by 334
Ogiwara, H., Ui, A., Otsuka, A., Satoh, H., Yokomi, I., Nakajima, S., Yasui, A., Yokota, J., & Kohno, T. (2011) · Oncogene · doi:10.1038/onc.2010.592 · Cited by 304
Self-citationVulnerabilities of Mutant SWI/SNF Complexes in Cancer
Helming, K. C., Wang, X., & Roberts, C. W. M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.018 · Cited by 303
Oike, T., Ogiwara, H., Tominaga, Y., Ito, K., Ando, O., Tsuta, K., Mizukami, T., Shimada, Y., Isomura, H., Komachi, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4593 · Cited by 294
Self-citationBromodomain inhibitors and cancer therapy: From structures to applications
Pérez-Salvia, M., & Esteller, M. (2017) · Epigenetics · doi:10.1080/15592294.2016.1265710 · Cited by 292
Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma
Guan, B., Mao, T.-L., Panuganti, P. K., Kuhn, E., Kurman, R. J., Maeda, D., Chen, E., Jeng, Y.-M., Wang, T.-L., & Shih, I.-M. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318212782a · Cited by 286
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types
Jones, S., Li, M., Parsons, D. W., Zhang, X., Wesseling, J., Kristel, P., Schmidt, M. K., Markowitz, S., Yan, H., Bigner, D., et al. (2012) · Human Mutation · doi:10.1002/humu.21633 · Cited by 285
Vangamudi, B., Paul, T. A., Shah, P. K., Kost-Alimova, M., Nottebaum, L., Shi, X., Zhan, Y., Leo, E., Mahadeshwar, H. S., Protopopov, A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3798 · Cited by 281
“However, as previously noted, nondetectable SMARCA4 protein levels (as assessed by immunoblotting) occur more often than predicted from mutation and CN analysis, suggesting that promoter methylation and epigenetic silencing may be additional oncogenic mechanisms for SMARCA4 loss (32).”
Lissanu Deribe, Y., Sun, Y., Terranova, C., Khan, F., Martinez-Ledesma, J., Gay, J., Gao, G., Mullinax, R. A., Khor, T., Feng, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0019-5 · Cited by 268
Yamamoto, S., Tsuda, H., Takano, M., Tamai, S., & Matsubara, O. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.189 · Cited by 259
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
Fillmore, C. M., Xu, C., Desai, P. T., Berry, J. M., Rowbotham, S. P., Lin, Y.-J., Zhang, H., Marquez, V. E., Hammerman, P. S., Wong, K.-K., et al. (2015) · Nature · doi:10.1038/nature14122 · Cited by 255
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
Targeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities
Momcilovic, M., & Shackelford, D. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.261 · Cited by 97
Metadata
- Authors
- Medina, P. P., Romero, O. A., Kohno, T., Montuenga, L. M., Pio, R., Yokota, J., & Sanchez-Cespedes, M.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2008-04-03
- Volume
- 29
- Issue
- 5
- Pages
- 617-622
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2017166332
- Cited by
- 273
- References
- 21
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.